It has been a challenging month for Bethesda, Maryland-based Gain Therapeutics, Inc. Shares of the company have fallen dramatically since 14 June, when it priced a public offering to raise $11m.
The drop has nearly halved Gain’s valuation, to roughly $23m (as of 19 June), irking CEO Matthias Alder, a 30-year...